direct oral anticoagulants | sciencenewsnet.in

Breaking News

Recycling CFRP waste is a challenge, but we’ve found a way to make it work

Argonne National Laboratory and the University of Illinois Chicago launch the George Crabtree Institute for Discovery and Sustainability

What women want: Female experiences to manage pelvic pain

Predicting Ovarian Cancer Relapse

Octopus Inspires New Suction Mechanism for Robots

Opioid dependence remains high but stable in Scotland, new surveillance report finds

MSU expert: The cicadas are coming

Soil Bacteria Link their Life Strategies to Soil Conditions

Cleveland Clinic Launches New Women’s Comprehensive Health and Research Center

Telemedicine Can Help Change Care for the Better — If We Get the Rules Right

18 Apr, 2024

DOACs more effective, cost-effective compared to LMWH for cancer-associated thrombosis

December 26, 2022 sarah JonasResearch Results

A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT). These findings may inform decisions on the clinical level as well as policy decisions. The analysis is published in Annals of Internal Medicine.

Mayo Clinic study provides clarity on use of anticoagulants in gastrointestinal cancers

June 3, 2021 sarah JonasResearch Results

A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers. The findings were published Wednesday, June 2, in Mayo Clinic Proceedings.